Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus BVD vs BVD in relapsed/refractory multiple myeloma
ChiCTR2100049723Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tucidinostat in multiple myeloma (MM) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Overall response rate and Related adverse reactions. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100049723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049723.